Subsidiary of China Meheco passes generic drug evaluation

China Meheco has announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, has received approval from the National Medical Products Administration (NMPA) for its Clindamycin Phosphate Injection to pass the generic drug consistency evaluation. This approval signifies that Tianfang Pharmaceutical's product demonstrates equivalent quality and efficacy to the original branded drug. The Clindamycin Phosphate Injection, used for serious infections caused by susceptible anaerobic bacteria, is available in two specifications: 4ml:0.6g and 2ml:0.3g. According to market data, the drug had sales of approximately CNY 225 million in China's public hospitals and community health centers in 2024. China Meheco has invested approximately CNY 7.5 million in this project. The company believes this approval will facilitate market share expansion and contribute valuable experience for future generic drug consistency evaluation efforts.